Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug Rezetecan + Immunotherapy in MMRp Endometrial Cancer
NCT07684599Phase 3Recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Primary completion
- Jul 2029
- Countries
- 3
01
Overview
A Phase 3 trial of mocertatug rezetecan in endometrial cancer (EC), sponsored by GSK. Started Sep 2026; status: recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07684599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684599.